PL2837680T3 - Hodowla ssaczych komórek - Google Patents

Hodowla ssaczych komórek

Info

Publication number
PL2837680T3
PL2837680T3 PL14187232T PL14187232T PL2837680T3 PL 2837680 T3 PL2837680 T3 PL 2837680T3 PL 14187232 T PL14187232 T PL 14187232T PL 14187232 T PL14187232 T PL 14187232T PL 2837680 T3 PL2837680 T3 PL 2837680T3
Authority
PL
Poland
Prior art keywords
culture
mammalian cells
mammalian
cells
Prior art date
Application number
PL14187232T
Other languages
English (en)
Inventor
Brian D. Follstad
Rebecca E. Mccoy
Arvia E. Morris
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2837680(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of PL2837680T3 publication Critical patent/PL2837680T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10—Perfusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL14187232T 2011-07-01 2012-06-29 Hodowla ssaczych komórek PL2837680T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161503737P 2011-07-01 2011-07-01
EP12738674.6A EP2726600B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
EP14187232.5A EP2837680B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture
PCT/US2012/045070 WO2013006479A2 (en) 2011-07-01 2012-06-29 Mammalian cell culture

Publications (1)

Publication Number Publication Date
PL2837680T3 true PL2837680T3 (pl) 2020-08-10

Family

ID=46579326

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12738674T PL2726600T3 (pl) 2011-07-01 2012-06-29 Hodowla ssaczych komórek
PL14187232T PL2837680T3 (pl) 2011-07-01 2012-06-29 Hodowla ssaczych komórek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12738674T PL2726600T3 (pl) 2011-07-01 2012-06-29 Hodowla ssaczych komórek

Country Status (23)

Country Link
US (7) US11292829B2 (pl)
EP (2) EP2726600B1 (pl)
JP (1) JP5897708B2 (pl)
KR (8) KR101857380B1 (pl)
CN (2) CN107988166B (pl)
AU (5) AU2012279230C1 (pl)
BR (2) BR122021007265B1 (pl)
CA (2) CA2838695C (pl)
CL (2) CL2013003792A1 (pl)
CY (2) CY1118863T1 (pl)
DK (2) DK2837680T3 (pl)
EA (1) EA039023B1 (pl)
ES (2) ES2788132T3 (pl)
HU (2) HUE049119T2 (pl)
IL (6) IL310968B2 (pl)
LT (2) LT2837680T (pl)
MX (2) MX351974B (pl)
PL (2) PL2726600T3 (pl)
PT (2) PT2726600T (pl)
SG (1) SG10201702537RA (pl)
SI (2) SI2837680T1 (pl)
WO (1) WO2013006479A2 (pl)
ZA (1) ZA201309372B (pl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
BRPI0716762A2 (pt) 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
TWI610936B (zh) 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2838695C (en) * 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
CN104011073B (zh) 2011-10-18 2017-08-25 科荣生生物科学公司 使用氨基酸稳定的依那西普制剂
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2869816A4 (en) 2012-07-09 2016-04-20 Coherus Biosciences Inc ETANERCEPT FORMULATIONS WITH CLEAR REDUCTION OF SUBVISIBLE PARTICLES
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
RS57013B1 (sr) 2012-09-11 2018-05-31 Coherus Biosciences Inc Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom
US20140199728A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
MX362922B (es) * 2013-03-26 2019-02-25 Coherus Biosciences Inc Método de producción de proteínas.
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
CA2929077C (en) * 2013-10-31 2024-05-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
AU2014376225C1 (en) 2014-01-13 2025-06-05 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
EP3099324B1 (en) 2014-01-30 2020-04-01 Coherus Biosciences, Inc. Perfusion media
ES2995052T3 (en) 2014-04-23 2025-02-05 Juno Therapeutics Inc Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
CN106687575B (zh) 2014-06-04 2021-04-30 美国安进公司 用于收获哺乳动物细胞培养物的方法
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TW202246486A (zh) * 2014-06-09 2022-12-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
JP6530171B2 (ja) * 2014-09-09 2019-06-12 旭化成メディカル株式会社 培養産生物の回収方法
SI3227454T1 (sl) * 2014-12-01 2020-06-30 Amgen Inc. Postopek za manipuliranje ravni vsebnosti glikana glikoproteina
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105385731B (zh) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 一种表达重组八因子的灌注培养方法
WO2017120359A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
KR102593407B1 (ko) * 2016-03-02 2023-10-24 론자 리미티드 개선된 발효 공정
US20200377918A1 (en) * 2017-03-31 2020-12-03 Boehringer Ingelheim International Gmbh Perfusion medium
US11702628B2 (en) 2017-03-31 2023-07-18 Boehringer Ingelheim International Gmbh Perfusion medium for culturing mammalian cells and reducing cell bleed in a perfusion cell culture
EP3639171A4 (en) * 2017-06-16 2021-07-28 Cytiva Sweden AB PROCESS FOR PREDICTING THE RESULT AND MODELING A PROCESS IN A BIOREACTOR
WO2019032927A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF
IL273549B2 (en) 2017-10-06 2023-10-01 Lonza Ag Automated control of cell culture using Raman spectroscopy
TW202538049A (zh) 2017-10-16 2025-10-01 美商再生元醫藥公司 灌注生物反應器及相關使用方法
WO2019089855A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019113557A1 (en) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
EP4368699A3 (en) * 2018-07-03 2024-09-11 Bristol-Myers Squibb Company Methods of producing recombinant proteins
CA3108657A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
WO2020142445A1 (en) 2018-12-31 2020-07-09 Repligen Corporation Filter for mammalian cell culture perfusion and clarification with hydrophobic hollow fiber
CN114729306B (zh) * 2019-09-27 2025-10-21 勃林格殷格翰国际公司 浓缩灌注培养基
JP2023537760A (ja) * 2020-08-14 2023-09-05 ブリストル－マイヤーズ スクイブ カンパニー タンパク質の製造工程
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
JP7808097B2 (ja) 2020-09-22 2026-01-28 ブリストル－マイヤーズ スクイブ カンパニー 治療タンパク質を生産するための方法
CN114574430A (zh) * 2022-03-22 2022-06-03 成都博宠生物科技有限公司 一种Expi293F细胞培养方法
CN115287251A (zh) * 2022-08-25 2022-11-04 无锡药明生物技术股份有限公司 间歇性灌流联合分批流加培养
JP2025529258A (ja) 2022-09-06 2025-09-04 アムジェン インコーポレイテッド リーン灌流細胞培養法
IL319172A (en) 2022-09-16 2025-04-01 Amgen Inc Method for collecting products in perfusate cultures
WO2024220354A1 (en) * 2023-04-15 2024-10-24 Puerto Rico Science Technology & Research Trust Methods of producing hiv-1 envelope glycoproteins and guanosine microparticles thereof
WO2025029614A1 (en) 2023-07-28 2025-02-06 Amgen Inc. A method for equilibrating a chromatography medium
CN116790483B (zh) * 2023-08-22 2023-10-20 苏州依科赛生物科技股份有限公司 一种cho细胞无血清培养基及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4499064A (en) 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US7037721B1 (en) * 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US20030036505A1 (en) 2000-09-25 2003-02-20 Human Genome Sciences, Inc. Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon
JP2004532642A (ja) 2001-06-13 2004-10-28 ジェネンテック・インコーポレーテッド 動物細胞の培養方法と動物細胞でのポリペプチド産生
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003083066A2 (en) 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production
CN104388324A (zh) * 2004-03-05 2015-03-04 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
CN1332024C (zh) * 2004-06-09 2007-08-15 中国科学院大连化学物理研究所 一种海绵细胞的微载体三维培养方法
ATE505219T1 (de) 2004-07-07 2011-04-15 Coloplast As Katheter enthaltend estane 58212
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
CA2585547A1 (en) * 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
DK2634242T3 (en) 2006-07-14 2017-05-22 Patheon Holdings I B V IMPROVED PROCEDURE FOR CULTURING CELLS
WO2008024769A2 (en) * 2006-08-21 2008-02-28 Raven Biotechnologies, Inc. Intensified perfusion production method
RU2520810C2 (ru) 2006-11-08 2014-06-27 Вайет Рационально разработанные среды для культивирования клеток
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
ES2657055T3 (es) 2007-08-09 2018-03-01 Wyeth Llc Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
CA2734922C (en) 2008-09-15 2020-01-14 Genentech, Inc. Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
US8313926B2 (en) 2009-07-31 2012-11-20 Baxter International Inc. Methods for expressing ADAMTS proteins in cell culture medium supplemented with zinc
BR112012002974B1 (pt) 2009-08-11 2022-06-07 Genentech, Inc Processo para produzir um anticorpo em uma célula hospedeira de célula ovário de hamster chinês (cho) expressando o referido polipeptídeo
SMT201700529T1 (it) 2009-11-17 2018-01-11 Squibb & Sons Llc Metodi per un'aumentata produzione di proteine
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
EP3156421B1 (en) * 2010-11-01 2018-06-06 Symphogen A/S Pan-her antibody composition
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
CA2838695C (en) * 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
CA2929077C (en) 2013-10-31 2024-05-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
RU2021135165A (ru) * 2015-11-17 2021-12-29 Пфайзер Инк. Среды и способы ферментации для производства полисахаридов в бактериальной клеточной культуре

Also Published As

Publication number Publication date
KR20160075814A (ko) 2016-06-29
HK1206057A1 (en) 2015-12-31
AU2023201127A1 (en) 2023-03-30
BR122021007265B1 (pt) 2022-02-22
AU2020281075C1 (en) 2025-06-26
CN103827292A (zh) 2014-05-28
CN103827292B (zh) 2018-01-26
LT2726600T (lt) 2017-05-25
AU2020281075B2 (en) 2022-12-22
AU2023201127B2 (en) 2025-10-16
US11685772B2 (en) 2023-06-27
MX387489B (es) 2025-03-18
IL288509A (en) 2022-01-01
EP2726600B1 (en) 2017-02-15
HUE033279T2 (en) 2017-11-28
CN107988166B (zh) 2022-03-15
AU2018203972A1 (en) 2018-06-21
AU2016244255A1 (en) 2016-10-27
US11292829B2 (en) 2022-04-05
CN107988166A (zh) 2018-05-04
EA039023B1 (ru) 2021-11-23
CY1123146T1 (el) 2021-12-31
ZA201309372B (en) 2014-08-27
SI2837680T1 (sl) 2020-07-31
HUE049119T2 (hu) 2020-09-28
KR20250021605A (ko) 2025-02-13
KR20230114317A (ko) 2023-08-01
US20210061888A1 (en) 2021-03-04
KR20200051046A (ko) 2020-05-12
WO2013006479A3 (en) 2013-03-28
US11634476B2 (en) 2023-04-25
PT2837680T (pt) 2020-04-17
SG10201702537RA (en) 2017-04-27
JP5897708B2 (ja) 2016-03-30
KR20240005106A (ko) 2024-01-11
IL310968B1 (en) 2024-11-01
AU2020281075A1 (en) 2021-01-07
DK2837680T3 (da) 2020-04-27
IL297998B1 (en) 2024-03-01
AU2012279230A1 (en) 2014-01-09
US11673941B2 (en) 2023-06-13
KR102558247B1 (ko) 2023-07-24
MX351974B (es) 2017-11-06
AU2012279230C1 (en) 2025-06-19
KR20180050433A (ko) 2018-05-14
US20200407427A1 (en) 2020-12-31
CL2013003792A1 (es) 2014-07-25
KR102108663B1 (ko) 2020-05-07
US20220185869A1 (en) 2022-06-16
CA2838695C (en) 2017-02-14
IL315908A (en) 2024-11-01
SI2726600T1 (sl) 2017-07-31
CY1118863T1 (el) 2018-01-10
CA2838695A1 (en) 2013-01-10
KR101857380B1 (ko) 2018-05-11
KR20220021008A (ko) 2022-02-21
BR112013033730A2 (pt) 2017-01-31
DK2726600T3 (en) 2017-05-15
EP2726600A2 (en) 2014-05-07
CA2952347A1 (en) 2013-01-10
BR112013033730B1 (pt) 2022-01-25
IL310968B2 (en) 2025-03-01
US20230117598A1 (en) 2023-04-20
EP2837680A1 (en) 2015-02-18
JP2014520534A (ja) 2014-08-25
IL288509B (en) 2022-12-01
US20230129523A1 (en) 2023-04-27
EP2837680B1 (en) 2020-02-26
ES2625045T3 (es) 2017-07-18
KR20140031375A (ko) 2014-03-12
WO2013006479A2 (en) 2013-01-10
AU2018203972C1 (en) 2025-06-26
IL288509B2 (en) 2023-04-01
CL2016001190A1 (es) 2017-06-09
KR101662412B1 (ko) 2016-10-04
ES2788132T3 (es) 2020-10-20
HK1197081A1 (en) 2015-01-02
US11827692B2 (en) 2023-11-28
PT2726600T (pt) 2017-04-24
MX2013014937A (es) 2014-04-16
AU2018203972B2 (en) 2020-09-17
US20140255993A1 (en) 2014-09-11
US20230227535A1 (en) 2023-07-20
IL297998B2 (en) 2024-07-01
EA201391826A1 (ru) 2014-04-30
IL297998A (en) 2023-01-01
KR102761360B1 (ko) 2025-02-05
IL229803B (en) 2020-11-30
AU2012279230B2 (en) 2016-08-18
IL278430B (en) 2022-01-01
PL2726600T3 (pl) 2017-08-31
KR102358951B1 (ko) 2022-02-08
LT2837680T (lt) 2020-07-10
IL310968A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
IL288509A (en) Mammalian cell culture
IL288241A (en) Improved methods of cell culture for adoptive cell therapy
IL271005A (en) Improved methods of cell culture for adoptive cell therapy
EP2681306A4 (en) CELL CULTURE SYSTEM
IL229879B (en) Culture media for stem cells
EP3699264C0 (en) THREE-DIMENSIONAL CELL CULTIVATION
FI20106121A7 (fi) Soluviljelymateriaali
EP2759592A4 (en) ADHÄSIONSZELLKULTURVERFAHREN
HUE040455T2 (hu) T-sejt aktiválás inhibitorai
EP2788470A4 (en) CLOSED BIOREACTORS
EP3375462C0 (en) Improvements to immobilised biological entities
EP2772530A4 (en) CELL CULTURE ASSAY
IL227552B (en) Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
DK3144319T3 (da) Cellekultursammensætning indeholdende laminin-521
EP2717924A4 (en) MODULATION OF BETA CELL PROLIFERATION IN THE PANCREATIC GLAND
EP2794841A4 (en) BIOREACTOR
DK2751254T3 (da) Forbedret levedygtighed af probiotiske mikroorganismer under anvendelse af poly-gamma-glutaminsyre
DK2768944T3 (da) Tilsætning af jern til forbedring af cellekultur
HRP20200794T1 (hr) Keramidaza i diferencijacija stanica
SG11201500386WA (en) Cell culture of corneal endothelial cells
EP2664004A4 (en) PHOTOVOLTAIC CELLS
FI20100388A0 (fi) Viljelymenetelmä
EP2679667A4 (en) Xylose-fermenting microorganism
GB201007855D0 (en) Bioreactor for the culture of cells